{"id":42948,"date":"2018-09-03T14:54:32","date_gmt":"2018-09-03T13:54:32","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=42948"},"modified":"2018-09-11T11:42:50","modified_gmt":"2018-09-11T10:42:50","slug":"ann-robinsons-research-reviews-3-september-2018","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/","title":{"rendered":"Ann Robinson&#8217;s research reviews\u20143 September 2018"},"content":{"rendered":"<p class=\"standfirst\">This week we introduce the next of our three new columnists who will be writing our weekly research reviews<\/p>\n<p><!--more--><\/p>\n<p><em><strong><a href=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft size-full wp-image-42949\" src=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg\" alt=\"\" width=\"160\" height=\"160\" srcset=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg 160w, https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2-150x150.jpg 150w\" sizes=\"auto, (max-width: 160px) 100vw, 160px\" \/><\/a>Ann Robinson<\/strong> is an NHS GP and health writer\/broadcaster. She works within her local community, is a trustee of the Anthony Nolan charity.<\/em><\/p>\n<p><b><u>Fat-busting diabetes drug<\/u><\/b><\/p>\n<p><a href=\"https:\/\/www.thelancet.com\/journals\/lancet\/article\/PIIS0140-6736(18)31773-2\/fulltext\">A much discussed study in the <em>Lancet<\/em><\/a> looked at whether semaglutide is effective at promoting weight loss in non-diabetics and compared its efficacy and safety profiles with liraglutide\u2014another glucagon-like-peptide-1 (GLP-1) analogue, and with placebo. It\u2019s funded by pharma and only a phase 2 trial, but is a randomised double blind trial with 957 participants and a follow-up period of a year. All doses were by weekly subcut injection and the primary endpoint was percentage weight loss at 52 weeks. The group that lost the most weight (-13.8%) comprised people on the highest dose (0.4 mg) of semaglutide. All semaglutide doses were generally well tolerated. The most common side effect is nausea, which is dose related and tends to occur with other GLP-1 receptor agonists too. Semaglutide appears to reduce hunger and cravings for food. It\u2019s not the first diabetes drug that can result in weight loss; our old standbys metformin and liraglutide (approved by NICE) do too, although this study suggests that semaglutide may have the edge on liraglutide. The safety data is reassuring; nevertheless, patients still need counselling about the possible warning signs of thyroid cancer neck mass, difficulty breathing, swallowing, or persistent hoarseness.<\/p>\n<p><b><u>Speechless<\/u><\/b><\/p>\n<p><span style=\"font-weight: 400\">Aphasia is a particularly cruel and frustrating problem that affects up to a<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3057942\/\"> <span style=\"font-weight: 400\">third of people who have a stroke<\/span><\/a><span style=\"font-weight: 400\">. The impairment in ability to communicate usually occurs in left middle cerebral artery stroke and despite huge strides in treating acute stroke, the treatment of aphasia has been a bit of a Cinderella subject. This randomised <\/span><a href=\"https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2696529\"><span style=\"font-weight: 400\">trial<\/span><\/a><span style=\"font-weight: 400\"> used a<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4639404\/\"> <span style=\"font-weight: 400\">futility (non superiority) design<\/span><\/a> <span style=\"font-weight: 400\">to test transcranial direct current stimulation (tDCS) given as an adjunct during speech therapy among 74 patients with long-term aphasia. They received three weeks of therapy coupled with either anodal tDCS or sham tDCS. tDCS i<\/span><span style=\"font-weight: 400\">s a non-invasive, painless brain stimulation treatment that uses direct electrical currents to stimulate specific parts of the brain. In this study, i<\/span><span style=\"font-weight: 400\">mprovement using anodal tDCS compared with sham did not find evidence that further investigation of anodal tDCS was futile. This suggests that giving anodal tDCS during speech therapy for post stroke aphasia, is worth further research.<\/span><\/p>\n<p><b><u>Pregabalin and opioids increases risk of opioid-related deaths<\/u><\/b><\/p>\n<p><span style=\"font-weight: 400\">Many patients in chronic pain are prescribed both pregabalin and opioids. There is a known increased risk of harm from taking the two together, but how big a risk is it? Pregabalin, first used as an anticonvulsant, is now widely prescribed for chronic pain. There\u2019s a growing illicit market for pregabalin and gabapentin, because they can make you feel relaxed and calm or euphoric. They enhance the euphoric effect of other drugs like opioids and<\/span><a href=\"https:\/\/www.england.nhs.uk\/south\/wp-content\/uploads\/sites\/6\/2018\/01\/nhs-cd-newsletter-pregabalin.pdf\"> <span style=\"font-weight: 400\">NHS England<\/span><\/a> <span style=\"font-weight: 400\">has warned that there\u2019s an increased risk of harm when they are used in combination with opioids and\/or alcohol. Recent<\/span><a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5626029\/\"> <span style=\"font-weight: 400\">evidence<\/span><\/a><span style=\"font-weight: 400\"> has shown that taking gabapentin and opioids together is associated with opioid-related deaths. This large, case-control<\/span><a href=\"http:\/\/annals.org\/aim\/article-abstract\/2697572\/pregabalin-risk-opioid-related-death-nested-case-control-study\"> <span style=\"font-weight: 400\">study<\/span><\/a> <span style=\"font-weight: 400\">from Ontario (with participants aged between 15-105) <\/span><span style=\"font-weight: 400\">found that drug interaction involving pregabalin and opioids is similar to that previously observed with gabapentin and opioids. It\u2019s important because over half of the Ontario residents who started pregabalin were already taking an opioid. Gabapentin carries a warning about co-prescribing with an opioid, but pregabalin doesn\u2019t. Sounds like it should.<\/span><\/p>\n<p><b><u>Battling to reduce opioid prescribing\u2014do guidelines work?<\/u><\/b><\/p>\n<p><span style=\"font-weight: 400\">On the subject of opioids, everyone now realises that they\u2019re overprescribed, overused, and responsible for many excess deaths from overdose. But how to persuade doctors to prescribe more responsibly? In March 2016, <\/span><span style=\"font-weight: 400\">the Centers for Disease Control and Prevention (CDC) released the<\/span><a href=\"https:\/\/www.cdc.gov\/mmwr\/volumes\/65\/rr\/rr6501e1.htm\"> <i><span style=\"font-weight: 400\">Guideline for Prescribing Opioids for Chronic Pain<\/span><\/i><\/a><i><span style=\"font-weight: 400\">. <\/span><\/i><span style=\"font-weight: 400\">Did prescribing habits change? <a href=\"http:\/\/annals.org\/aim\/fullarticle\/2698111\/opioid-prescribing-united-states-before-after-centers-disease-control-prevention\">This study analysed<\/a> prescribing data in the US (2012-17); the rate of high-dosage prescriptions, percentage of patients prescribed both opioids and benzodiazepines, and overall opioid prescribing rate all fell to a small extent from 2012 to 2016, and then at a faster rate after the guidelines were published. This analysis can\u2019t prove that the guideline directly caused the change in prescribing, but there does seem to be a clear temporal link. \u201cGuidelines may be effective in changing prescribing practices,\u201d say the authors. It may not be a ringing endorsement, but it will cheer people who love guidelines.<\/span><\/p>\n<p><b><u>Progressive Multiple Sclerosis<\/u><\/b><\/p>\n<p><span style=\"font-weight: 400\">Progressive multiple sclerosis is a devastating condition and we still have so little to offer in terms of treatment.<\/span><a href=\"https:\/\/bnf.nice.org.uk\/drug\/ocrelizumab.html\"> <span style=\"font-weight: 400\">Ocrelizumab<\/span><\/a> <span style=\"font-weight: 400\">has been granted a European Commission licence and<\/span><a href=\"https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10153\"> <span style=\"font-weight: 400\">NICE<\/span><\/a><span style=\"font-weight: 400\"> is due to announce its decision on its use in primary progressive MS next month. Another, different type of drug offering potential hope is ibudilast, a phosphodiesterase inhibitor. <a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa1803583?query=featured_home\">A phase 2 trial<\/a> compared the rate of brain atrophy over 96 weeks in 255 patients with <\/span><span style=\"font-weight: 400\">primary or secondary progressive MS on oral ibudilast compared to a matched group given placebo. Those given ibudilast showed slower progression of brain atrophy than placebo, but experienced more side effects (gastrointestinal upset, headache, and depression). A phase 3 trial is now needed to test whether ibudilast improves symptoms although it is notoriously difficult to show a convincing positive effect in progressive MS as so much irreversible damage has already occurred. A drug like ibudilast that may slow progression is encouraging, but a treatment that can halt or reverse the condition still seems a long way off.<\/span><\/p>\n<p><b><u>Head injury\u2014a headache for doctors<\/u><\/b><\/p>\n<p><span style=\"font-weight: 400\">It\u2019s a common nightmare scenario for doctors in general practice or emergency rooms. You see a patient who has bumped their head and has a headache. We all know that <\/span><span style=\"font-weight: 400\">the risk of intracranial complications after minor head injury is low and we can\u2019t, and shouldn\u2019t, order a CT scan of the head in all cases. But how do we reliably identify those that need close observation and even neurosurgical intervention? How do we make sure that we don\u2019t miss a potentially fatal, but surgically salvageable intracranial bleed? You can take your pick from a range of decision rules in computed tomography (CT) that are designed to identify those patients at higher risk of intracranial complications after a seemingly minor head injury. <a href=\"https:\/\/www.bmj.com\/content\/362\/bmj.k3527\">A multi-centre Dutch study<\/a> has compared CHIP with the other three externally validated tools. The upshot is that CHIP looks good; reasonably sensitive in picking up neurosurgical lesions, more chance of benefit at intermediate thresholds of performing CT scans, and overall far fewer scans than if you scan everyone with a minor head injury. It\u2019s a help but no guarantee; minor head injury remains a headache for doctors on the front line who have to make the call about ordering a CT scan-or not. \u00a0<\/span><\/p>\n<p><em><strong>Ann Robinson<\/strong> is an NHS GP and health writer\/broadcaster. She works within her local community, is a trustee of the Anthony Nolan charity.<\/em><\/p>\n<p><em><strong>Competing interests<\/strong>: None declared.\u00a0<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This week we introduce the next of our three new columnists who will be writing our weekly research reviews [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/\">More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[18902],"tags":[],"class_list":["post-42948","post","type-post","status-publish","format-standard","hentry","category-weekly-research-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ann Robinson&#039;s research reviews\u20143 September 2018 - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ann Robinson&#039;s research reviews\u20143 September 2018 - The BMJ\" \/>\n<meta property=\"og:description\" content=\"This week we introduce the next of our three new columnists who will be writing our weekly research reviews [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-03T13:54:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-09-11T10:42:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Ann Robinson&#8217;s research reviews\u20143 September 2018\",\"datePublished\":\"2018-09-03T13:54:32+00:00\",\"dateModified\":\"2018-09-11T10:42:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/\"},\"wordCount\":1162,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/09\\\/ann_robinson2.jpg\",\"articleSection\":[\"Weekly review of medical journals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/\",\"name\":\"Ann Robinson's research reviews\u20143 September 2018 - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/09\\\/ann_robinson2.jpg\",\"datePublished\":\"2018-09-03T13:54:32+00:00\",\"dateModified\":\"2018-09-11T10:42:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/09\\\/ann_robinson2.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/09\\\/ann_robinson2.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2018\\\/09\\\/03\\\/ann-robinsons-research-reviews-3-september-2018\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ann Robinson&#8217;s research reviews\u20143 September 2018\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ann Robinson's research reviews\u20143 September 2018 - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/","og_locale":"en_US","og_type":"article","og_title":"Ann Robinson's research reviews\u20143 September 2018 - The BMJ","og_description":"This week we introduce the next of our three new columnists who will be writing our weekly research reviews [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2018-09-03T13:54:32+00:00","article_modified_time":"2018-09-11T10:42:50+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg","type":"","width":"","height":""}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Ann Robinson&#8217;s research reviews\u20143 September 2018","datePublished":"2018-09-03T13:54:32+00:00","dateModified":"2018-09-11T10:42:50+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/"},"wordCount":1162,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg","articleSection":["Weekly review of medical journals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/","url":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/","name":"Ann Robinson's research reviews\u20143 September 2018 - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg","datePublished":"2018-09-03T13:54:32+00:00","dateModified":"2018-09-11T10:42:50+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/09\/ann_robinson2.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2018\/09\/03\/ann-robinsons-research-reviews-3-september-2018\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Ann Robinson&#8217;s research reviews\u20143 September 2018"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=42948"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/42948\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=42948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=42948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=42948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}